NOKOMIS, Fla. -- (BUSINESS WIRE) -- The next generation of advanced pharmaceutical technologies could be poised to fuel remarkable growth in the $60 billion global drug delivery market, and Rainbow Biosciences—the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC)—plans to be right in the middle of the action.
New drug delivery methods are seen by some pharmaceutical giants as a crucial growth generator, and new innovations are spreading across the healthcare sector. Many experts believe that personalized medicine is the future of healthcare, and customized drug delivery has the potential to drastically change the way value is assessed and compensated in the U.S. healthcare system.
RBCC is working hard to capitalize on the changing drug-delivery paradigm by partnering with key players in the field. The company is now in talks with an emerging company that owns technology with the potential to enable selective, site-specific delivery, allowing for lower drug concentrations and greatly reducing the risk of drug toxicity. In addition to helping millions of patients struggling with chronic conditions, this bold new technology can also extend the patent life cycles of drugs, giving potential pharmaceutical partners a tremendous market advantage.
For more information on Rainbow BioSciences’ current projects, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.